Since 2015, our Patient Value Strategy has been the driver of UCB’s approach to delivering value for patients. Our operational model puts patients and their individual experiences at the heart of everything we do – from discovery to development to delivery.

By 2025, UCB aims to be a leader in specific patient populations and to provide an increasing number of people with severe diseases the freedom to live their best possible lives. Guided by our Patient Value Strategy and focusing on specific patient populations, our ambition is to deliver unique outcomes and the best experience to all patients who need our solutions, in a way which is viable for patients, for society, and for UCB.

Looking forward, we continue to aspire to become the patient-preferred biopharma leader – leveraging the different dimensions of our business to deliver sustainable value for patients, our employees, society, and our shareholders – to guide us while we learn and adapt to new and challenging environments. We are convinced that our strategy is the way to ensure UCB’s future success and sustainable growth.

Learn more about the progress we made last year and our aspirations for the future in our 2019 Integrated Annual Report.